Orshe

Pharma Deal: Gilead will pay about $10.4 billion — about $11 billion, including options — for drug developer Pharmasset, the WSJ reports. Pharmasset’s board has approved the deal, which values the company at $137 per share, an 89% premium to Friday’s closing price. Pharmasset said last month it was expanding a trial of a treatment for hepatitis C and Gilead is also pursuing therapies for the disease, the paper says.

For those keeping score of the health-care overhaul law’s record in U.S. appeals courts, the tally now stands at three rulings for the Obama administration and one for the law’s opponents.

As the WSJ reports, the U.S. Court of Appeals for the District of Columbia Circuit ruled 2-1 that the health law’s individual mandate — that’s the requirement that most people carry health insurance or pay a penalty — doesn’t violate the Constitution.

Figuring Out a Cleanup: Efforts in Japan to figure out how to properly and quickly clean up the radiation from the Fukushima Daiichi nuclear accident have been hampered by a lack of leadership and diluted accountability, the WSJ reports. Making efforts even more difficult is uncertainty about the levels of contamination that pose a health hazard, the paper says.

Two U.S. appeals courts are now at loggerheads over the constitutionality of the health-care overhaul law.

As the WSJ reports, the U.S. Court of Appeals for the 11th Circuit in Atlanta ruled 2-1 that the individual mandate to purchase health insurance (or, of course, face a penalty), violates the Constitution. The court did say the law could go forward without the mandate, however — the whole thing doesn’t have to be thrown out if that provision goes. Here’s the decision.

Japanese government bans Fukushima beef after cattle feed in the area are found to have radiation levels 500 times the legal requirement. Video and image courtesy of Reuters.

Read more from the original source: Japan Bans Fukushima Beef Shipments/a>

Researchers are hoping a new analytic technique being used by Proctor & Gamble can someday help detect major diseases like cancer and Alzheimer’s disease. Shirley Wang reports from Paris. (Photo: AP Photo.)

Read the original post: Markets Hub: A New Clue in Alzheimer’s Detection/a>

No Hearing: The Supreme Court yesterday rejected an appeal from insurers and other payers who said they paid too much for Eli Lilly’s antipsychotic drug Zyprexa because the drug company misrepresented the benefits of the medication, the WSJ reports. A lower court had ruled that there wasn’t a sufficient link between the high prices and Lilly’s marketing practices; the Supreme Court won’t hear a challenge to that ruling.